Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
767.700.32%
QQQ
720.030.15%
BTC/USD
78724.760.4622%
DIA
528.870.98%
GLD
402.031.17%
TLT
82.070.17%

TScan Therapeutics Inc (TCRX) Stock Price, Quote, News & History

TCRXNASDAQ
Trade with Public
Trade with Public
$0.3504
-0.0411-10.5%
Last update: Sep 8, 2:14 PM
PRO
Why Is It Moving?™:TScan Therapeutics shares are trading lower after HC Wainwright & Co. downg...
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

TScan Therapeutics (TCRX) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$0.38
Close
-
Volume / Avg.
1.37M / 773.37K
Day Range
$0.33 - $0.38
52 Wk Range
0.35 - 2.57
Market Cap
$23.75M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
19
Short Interest
3.39%
Days to Cover
4.24

Recent TScan Therapeutics Inc News

Crude Oil Moves Higher; US Factory Orders Rise In July

U.S. stocks rose mid-session, led by materials; factory orders beat estimates. Linkhome, Purple Biotech and GitLab surged, while Tscan and Credo fell.
Avi Kapoor

TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction

The strategic pivot focuses TScan's efforts on developing in vivo-engineered TCR-T therapies.
Vandana Singh

Dow Surges Over 200 Points; Ollie's Bargain Outlet Shares Gain After Q2 Earnings

U.S. stocks edged higher, led by the Dow and materials. Ollie’s beat EPS estimates; biotech and AI shares surged, while Tscan plunged 26%.
Avi Kapoor

This Kimberly-Clark Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Avi Kapoor

Why Is TScan Therapeutics Stock Gaining Today?

TScan Therapeutics' stock rises after announcing a $30 million financing deal with Lynx1, extending its cash runway into 2027.
Nabaparna Bhattacharya

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-116.28M
Investing Cash Flow (TTM)
46.87M
Financing Cash Flow (TTM)
172.00K
Free Cash Flow (TTM)
-118.44M
Capital Expenditure (TTM)
-2.16M
Net Change in Cash (TTM)
-69.24M

Analyst Trends and Forecast

2
Jun
1
Aug
2
Sep
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$17.27M
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
7.15
PB Ratio (TTM)
0.38
Earnings Yield % (TTM)
-229.89%
Earnings Yield % (FWD)
-227.33%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$1.02

Company Debt

Total Debt
$32.78M
LT Debt
$21.07M
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-
Total Cash
$100.16M
Debt to Equity
1.32
Issuance of Debt (TTM)
-
Repayment of Debt (TTM)
-

Key Statistics

Open
$0.38
Close
-
Volume / Avg.
1.37M / 773.37K
Day Range
$0.33 - $0.38
52 Wk Range
0.35 - 2.57
Market Cap
$23.75M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
19
Short Interest
3.39%
Days to Cover
4.24

About

Sector
Health Care
Industry
Biotechnology
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid ...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy TScan Therapeutics (TCRX) stock?

A

You can purchase shares of TScan Therapeutics (NASDAQ:TCRX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are TScan Therapeutics (TCRX) competitors?

Q

What is the forecast, or price target, for TScan Therapeutics (TCRX) stock?

A

TScan Therapeutics has a consensus price target of $6.67.

Q

What is the current price for TScan Therapeutics (TCRX)?

A

The stock price for TScan Therapeutics (NASDAQ: TCRX) is $0.3504 last updated September 8, 2026 at 2:14 PM EDT.

Q

Does TScan Therapeutics (TCRX) pay a dividend?

A

There are no upcoming dividends for TScan Therapeutics.

Q

When is TScan Therapeutics (NASDAQ:TCRX) reporting earnings?

A

TScan Therapeutics does not have any upcoming earnings scheduled.

Q

Is TScan Therapeutics (TCRX) going to split?

A

There is no upcoming split for TScan Therapeutics.

Q

What sector and industry does TScan Therapeutics (TCRX) operate in?

A

TScan Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved